Sfoglia per Autore
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
2025 Kim, Y; Nishio, S; Kim, S; Hasegawa, K; Dubot, C; Valeria Cáceres, M; Tewari, K; Lorusso, D; Lee, J; Liou, W; Li, K; Tekin, C; Colombo, N; Monk, B
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial
2025 Harano, K; Fossati, R; Pardo, B; Galli, F; Hudson, E; Antill, Y; Lee, C; Rabaglio, M; Heitz, F; Kolovetsiou-Kreiner, V; Lai, C; Biagioli, E; Manso, L; Nishio, S; Allan, K; Lee, Y; Uggeri, S; Redondo, A; Nakagawa, S; Au, E; Lombard, J; Gadducci, A; Takehara, K; Baldini, E; Palaia, I; Casanova, C; Ardizzoia, A; Bologna, A; Barretina-Ginesta, M; Colombo, N
Erratum to ‘Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101664] (International Journal of Gynecological Cancer (2025) 35(3), (S1048891X25001896), (10.1016/j.ijgc.2025.101664))
2025 Fumagalli, D; Jayraj, A; Olearo, E; Capasso, I; Hsu, H; Tzur, Y; Piedimonte, S; Jugeli, B; Santana, B; De Vitis, L; Caruso, G; Aletti, G; Colombo, N; Ramirez, P
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study
2025 Vergote, I; Copeland, L; Van Gorp, T; Laenen, A; Scambia, G; Thaker, P; Cibula, D; Colombo, N; Lea, J; Gonzalez-Martin, A; Korach, J; Sehouli, J; Monk, B; Heinzelmann-Schwarz, V; Berger, R; Buscema, J; Lau, S; Madry, R; Denys, H; Pepin, J; Salutari, V; Bagameri, A; Ardizzoia, A; Henry, S; Cecere, S; Hruda, M; Iglesias, D; Manso, L; Shai, A; O'Malley, D
Quantitative Proteomics and Phosphoproteomics Analysis of Patient-Derived Ovarian Cancer Stem Cells
2025 Franciosa, G; Nieddu, V; Battistini, C; Caffarini, M; Lupia, M; Colombo, N; Fusco, N; Olsen, J; Cavallaro, U
The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment
2025 De Vitis, L; Schivardi, G; Delfrati, S; Biffi, B; Viscardi, A; Rosanu, M; Ribero, L; Caruso, G; Rappa, A; Marinucci, L; Adorisio, R; Zanagnolo, V; Aletti, G; Barberis, M; Guerini-Rocco, E; Peccatori, F; Urbinati, A; Pino, I; Franchi, D; Betella, I; Colombo, N; Multinu, F
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
2025 Oza, A; Lisyanskaya, A; Fedenko, A; De Melo, A; Shparyk, Y; Rakhmatullina, I; Bondarenko, I; Colombo, N; Svintsitskiy, V; Biela, L; Nechaeva, M; Lorusso, D; Scambia, G; Cibula, D; Poka, R; Oaknin, A; Safra, T; Mackowiak-Matejczyk, B; Ma, L; Thomas, D; Lin, K; Mclachlan, K; Goble, S; Kristeleit, R
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study
2025 Valenza, C; Mongillo, M; Visconti, M; Katrini, J; Trapani, D; Boldrini, L; Guidi, L; Farfalla, A; Malengo, D; Caruso, G; Derio, S; Lapresa, M; Parma, G; Biagioli, E; Omodeo Salé, E; Curigliano, G; Colombo, N
External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer
2025 De Vitis, L; Schivardi, G; Gaeta, A; Caruso, G; Rosanu, M; Ribero, L; Fumagalli, D; Casarin, J; Betella, I; Bogani, G; Langstraat, C; Aletti, G; Colombo, N; Zanagnolo, V; Gandini, S; Multinu, F
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
2025 Olawaiye, A; Gladieff, L; O'Malley, D; Kim, J; Garbaos, G; Salutari, V; Gilbert, L; Mileshkin, L; Devaux, A; Hopp, E; Lee, Y; Oaknin, A; Scaranti, M; Kim, B; Colombo, N; Mccollum, M; Diakos, C; Clamp, A; Leiser, A; Balazs, B; Monk, B; Scandurra, G; Mcclung, E; Kaczmarek, E; Slomovitz, B; De La Cueva, H; De Carvalho Calabrich, A; Cassani, C; You, B; Van Gorp, T; Churruca, C; Caruso, G; Nicum, S; Bagameri, A; Artioli, G; Bodnar, L; Kang, S; Vergote, I; Kesner-Hays, A; Pashova, H; Pai, S; Tudor, I; Jubb, A; Lorusso, D
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
2025 Banerjee, S; Van Nieuwenhuysen, E; Aghajanian, C; D'Hondt, V; Monk, B; Clamp, A; Prendergast, E; Oaknin, A; Ring, K; Colombo, N; Holloway, R; Rodrigues, M; Chon, H; Gourley, C; Santin, A; Thaker, P; Gennigens, C; Newman, G; Salinas, E; Youssoufian, H; Moore, K; Lustgarten, S; O'Malley, D; Van Gorp, T; Grisham, R
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
2025 Quesada, S; Penault-Llorca, F; Matias-Guiu, X; Banerjee, S; Barberis, M; Coleman, R; Colombo, N; Defazio, A; Mcneish, I; Nogueira-Rodrigues, A; Oaknin, A; Pignata, S; Pujade-Lauraine, É; Rouleau, É; Ryška, A; Van Der Merwe, N; Van Gorp, T; Vergote, I; Weichert, W; Wu, X; Ray-Coquard, I; Pujol, P
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
2025 Oaknin, A; Monk, B; de Melo, A; Kim, H; Kim, Y; Lisyanskaya, A; Samouëlian, V; Lorusso, D; Damian, F; Chang, C; Gotovkin, E; Takahashi, S; Ramone, D; Maćkowiak-Matejczyk, B; Polastro, L; Alia, E; Colombo, N; Makarova, Y; Goh, J; Hasegawa, K; Mora, P; Pikiel, J; Srivastav, R; Rischin, D; Rubio, M; Perez, J; Yoo, S; Gao, B; Jamil, S; Seebach, F; Lowy, I; Mathias, M; Fury, M; Tewari, K
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
2025 Bogani, G; Moore, K; Ray-Coquard, I; Lorusso, D; Matulonis, U; Ledermann, J; González-Martín, A; Kurtz, J; Pujade-Lauraine, E; Scambia, G; Caruso, G; Raspagliesi, F; Colombo, N; Monk, B
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer
2025 Randall, L; Xiang, Y; Matsumoto, T; Giannarelli, D; Milla, D; Lopez, K; Acevedo, A; Vizkeleti, J; Salani, R; Nogueira-Rodrigues, A; Mejia, F; Korach, J; Akilli, H; Lee, J; Saevets, V; Samouelian, V; Sehouli, J; Tharavichikul, E; Sukhin, V; Colombo, N; Chang, C; Cueva, J; Lalondrelle, S; Petru, E; Szamreta, E; Nguyen, A; Yamada, K; Li, K; Pignata, S; Lorusso, D
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial
2025 Lorusso, D; Xiang, Y; Hasegawa, K; Scambia, G; Leiva, M; Ramos-Elias, P; Acevedo, A; Cvek, J; Randall, L; De Santana Gomes, A; Mejia, F; Helpman, L; Akilli, H; Lee, J; Saevets, V; Zagouri, F; Gilbert, L; Sehouli, J; Tharavichitkul, E; Lindemann, K; Colombo, N; Chang, C; Bednarikova, M; Zhu, H; Oaknin, A; Christiaens, M; Petru, E; Usami, E; Liu, P; Yamada, K; Toker, S; Keefe, S; Pignata, S; Duska, L
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
2025 Ledermann, J; Oza, A; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, J; Clamp, A; Scambia, G; Leary, A; Holloway, R; Gancedo, M; Fong, P; Goh, J; O'Malley, D; Armstrong, D; Banerjee, S; Garcia-Donas, J; Swisher, E; Lebreton, C; Konecny, G; Mcneish, I; Scott, C; Maloney, L; Goble, S; Lin, K; Coleman, R
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
2025 Concin, N; Matias-Guiu, X; Cibula, D; Colombo, N; Creutzberg, C; Ledermann, J; Mirza, M; Vergote, I; Abu-Rustum, N; Bosse, T; Chargari, C; Espenel, S; Fagotti, A; Fotopoulou, C; Gatius, S; Gonzalez-Martin, A; Lax, S; Levy, B; Lorusso, D; Macchia, G; Marth, C; Morice, P; Oaknin, A; Raspollini, M; Schwameis, R; Sehouli, J; Sturdza, A; Taylor, A; Westermann, A; Wimberger, P; Planchamp, F; Nout, R
Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
2025 Blons, H; Abdelli, J; Landman, S; Taly, V; Mulot, C; Laurent-Puig, P; You, B; Harter, P; Lorusso, D; Garcia-Garcia, Y; Polterauer, S; Hietanen, S; Colombo, N; Vergote, I; Kobayashi, H; De La Motte Rouge, T; Buderath, P; Cecere, S; Bataillon, G; Pujade-Lauraine, E; Ray-Coquard, I
Uterine leiomyosarcoma
2025 Bogani, G; Caruso, G; Ray-Coquard, I; Ramirez, P; Concin, N; Ngoi, N; Coleman, R; Mariani, A; Cliby, W; Leitao, M; Rustum, N; Casali, P; Gronchi, A; Vergote, I; Kroep, J; Enomoto, T; Takehara, K; Denys, H; Takano, M; Provencher, D; Wimberger, P; Kim, S; Kim, J; Zannoni, G; Tan, D; Casarin, J; Paolini, B; Chiappa, V; Raspagliesi, F; Cuccu, I; Di Donato, V; O'Malley, D; Mutch, D; Brown, J; Herrera, F; Colombo, N; Pignata, S; Scambia, G; Slomovitz, B; Monk, B
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile